FDA Grants Breakthrough Therapy Status to Larimar’s Nomlabofusp

Larimar Therapeutics ( (LRMR) ) has issued an announcement.

On February 24, 2026, Larimar Therapeutics said the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to its lead candidate nomlabofusp for treating adults and children with Friedreich’s ataxia, reflecting preliminary data showing increased frataxin levels and consistent improvements across several functional and fatigue measures versus natural history. Following a recent START program meeting, the FDA also signaled support for using skin frataxin as a surrogate endpoint, aligned on key efficacy and safety analyses and the design of a global confirmatory Phase 3 trial, and Larimar reiterated plans to submit a Biologics License Application in June 2026 supported by open-label data, a step that could materially advance its bid to bring a first disease-modifying therapy to this underserved rare disease community.

Larimar also reported that regulators agreed its proposed reference population from the FACOMS natural history database and exposure-response analyses are appropriate to underpin the filing, while underscoring that the adequacy of the safety database will be judged at review. The company intends to initiate screening for its global Phase 3 study in the second quarter of 2026, dose the first patient by mid-2026 and, if its accelerated approval strategy succeeds, position itself earlier in the Friedreich’s ataxia treatment landscape, potentially reshaping expectations for disease-modifying approaches in rare neuromuscular conditions and influencing stakeholders ranging from patients and clinicians to rare disease investors.

The most recent analyst rating on (LRMR) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Larimar Therapeutics stock, see the LRMR Stock Forecast page.

Spark’s Take on LRMR Stock

According to Spark, TipRanks’ AI Analyst, LRMR is a Neutral.

Score is held down primarily by weak financial performance (no revenue, widening losses, and significant cash burn) and bearish technical signals (below key moving averages with negative MACD). Positive clinical/regulatory progress for the lead program provides support, but valuation remains constrained by ongoing losses and no dividend.

To see Spark’s full report on LRMR stock, click here.

More about Larimar Therapeutics

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Its lead compound, nomlabofusp, is a frataxin protein replacement therapy in development for Friedreich’s ataxia, and the company aims to leverage its intracellular delivery platform to design additional fusion proteins for other rare disorders.

Average Trading Volume: 1,202,726

Technical Sentiment Signal: Strong Sell

Current Market Cap: $252.5M

See more insights into LRMR stock on TipRanks’ Stock Analysis page.